Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

Cited In for PubMed (Select 17474810)

1.

Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication.

Bernasconi R, Smieskova R, Schmidt A, Harrisberger F, Raschle NM, Lenz C, Walter A, Simon A, Riecher-Rössler A, Radue EW, Lang UE, Fusar-Poli P, Borgwardt SJ.

Neuroimage Clin. 2015 Apr 29;8:230-7. doi: 10.1016/j.nicl.2015.04.016. eCollection 2015.

2.

Gender differences in individuals at high-risk of psychosis: a comprehensive literature review.

Barajas A, Ochoa S, Obiols JE, Lalucat-Jo L.

ScientificWorldJournal. 2015;2015:430735. doi: 10.1155/2015/430735. Epub 2015 Jan 1.

3.

Prediction and prevention of the first psychotic episode: new directions and opportunities.

Piras S, Casu G, Casu MA, Orrù A, Ruiu S, Pilleri A, Manca G, Marchese G.

Ther Clin Risk Manag. 2014 Mar 28;10:241-53. doi: 10.2147/TCRM.S55770. eCollection 2014. Review.

4.

Self-awareness of functional impairment in individuals at clinical high-risk for psychosis.

Olvet DM, Carrión RE, Auther AM, Cornblatt BA.

Early Interv Psychiatry. 2015 Apr;9(2):100-7. doi: 10.1111/eip.12086. Epub 2013 Aug 22.

PMID:
23968457
5.

Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms.

Vahia IV, Lanouette NM, Golshan S, Fellows I, Mohamed S, Kasckow JW, Zisook S.

Indian J Psychiatry. 2013 Apr;55(2):144-8. doi: 10.4103/0019-5545.111452.

6.

Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.

Goff DC.

World Psychiatry. 2013 Jun;12(2):99-107. doi: 10.1002/wps.20026.

7.
8.

Assessing the potential to use neurocognition to predict who is at risk for developing bipolar disorder: a review of the literature.

Olvet DM, Burdick KE, Cornblatt BA.

Cogn Neuropsychiatry. 2013;18(1-2):129-45. doi: 10.1080/13546805.2012.724193. Epub 2012 Nov 9. Review.

9.

Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention.

Tandon N, Shah J, Keshavan MS, Tandon R.

Neuropsychiatry (London). 2012;2(4):345-353.

10.

Interventions for youth at high risk for bipolar disorder and schizophrenia.

McNamara RK, Strawn JR, Chang KD, DelBello MP.

Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):739-51. doi: 10.1016/j.chc.2012.07.009. Review.

11.

Obsessive compulsive symptoms in individuals at clinical risk for psychosis: association with depressive symptoms and suicidal ideation.

DeVylder JE, Oh AJ, Ben-David S, Azimov N, Harkavy-Friedman JM, Corcoran CM.

Schizophr Res. 2012 Sep;140(1-3):110-3. doi: 10.1016/j.schres.2012.07.009. Epub 2012 Jul 28.

12.

Temporal association of stress sensitivity and symptoms in individuals at clinical high risk for psychosis.

Devylder JE, Ben-David S, Schobel SA, Kimhy D, Malaspina D, Corcoran CM.

Psychol Med. 2013 Feb;43(2):259-68. doi: 10.1017/S0033291712001262. Epub 2012 Jun 1.

13.

At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk.

Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, McGuire P.

Schizophr Bull. 2013 Jul;39(4):923-32. doi: 10.1093/schbul/sbs060. Epub 2012 May 15. Review.

14.

Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis.

Bowie CR, McLaughlin D, Carrión RE, Auther AM, Cornblatt BA.

Schizophr Res. 2012 May;137(1-3):110-7. doi: 10.1016/j.schres.2012.02.008. Epub 2012 Feb 28.

15.

Evaluation and treatment of children and adolescents with psychotic symptoms.

Algon S, Yi J, Calkins ME, Kohler C, Borgmann-Winter KE.

Curr Psychiatry Rep. 2012 Apr;14(2):101-10. doi: 10.1007/s11920-012-0258-y. Review.

16.

Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.

Richtand NM, Ahlbrand R, Horn P, Tambyraja R, Grainger M, Bronson SL, McNamara RK.

Physiol Behav. 2012 May 15;106(2):171-7. doi: 10.1016/j.physbeh.2012.02.004. Epub 2012 Feb 9.

17.

Risk factors for psychosis: impaired social and role functioning.

Cornblatt BA, Carrión RE, Addington J, Seidman L, Walker EF, Cannon TD, Cadenhead KS, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Heinssen R, Lencz T.

Schizophr Bull. 2012 Nov;38(6):1247-57. doi: 10.1093/schbul/sbr136. Epub 2011 Nov 10.

18.

Prediction and prevention of schizophrenia: what has been achieved and where to go next?

Klosterkötter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S.

World Psychiatry. 2011 Oct;10(3):165-74.

19.

Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.

Bechdolf A, Müller H, Stützer H, Wagner M, Maier W, Lautenschlager M, Heinz A, de Millas W, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Brüne M, Krüger-Özgürdal S, Wobrock T, Riedel M, Klosterkötter J; PREVENT study group.

Schizophr Bull. 2011 Sep;37 Suppl 2:S111-21. doi: 10.1093/schbul/sbr083.

20.

Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.

Richtand NM, Ahlbrand R, Horn P, Stanford K, Bronson SL, McNamara RK.

J Psychiatr Res. 2011 Sep;45(9):1194-201. doi: 10.1016/j.jpsychires.2011.02.007. Epub 2011 Mar 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk